Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Sarcomas are a rare and diverse group of cancers that arise in the bones and soft tissues, often referred to as 'the forgotten cancer.' Rutgers Cancer Institute and RWJBarnabas Health expert Dr. Adam Berger shares more information on the disease during sarcoma awareness month.
"North American Cancer Center Clinical Research Capacity and Benchmarking in the Post-Pandemic Era" was published July 1 in JCO Oncology Practice, an American Society of Clinical Oncology (ASCO) Journal.
Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.
Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).
MD Anderson and Rice announced the creation of the Cancer Bioengineering Collaborative to develop innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment.
A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.
NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.
Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.
Bolstered by $6.3 million raised in donations, the Rutgers Board of Governors today approved the establishment of the William Hait Endowed Directorship at Rutgers Cancer Institute. Moving forward, the director of Rutgers Cancer Institute will be known as the William Hait Director.
20221027104337.jpg&width=400&height=400)
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers.
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
The Bristol-Myers Squibb Children’s Hospital (BMSCH) at Robert Wood Johnson University Hospital (RWJUH) and Rutgers Cancer Institute recently dedicated the new Pediatric Bone Marrow Transplantation and Cellular Therapy Program recognizing the many donors who supported the program.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right